News

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Live webcast on Wednesday, July 24 th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. As part of the event, Brad Hauser, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook.

07/22/2024

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement

Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company's agreement to license FDA-cleared ablation technology from RF Innovations, Inc.

07/18/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

What is Autonomix Medical, Inc. Common Stock's stock price?

The price of Autonomix Medical, Inc. Common Stock (AMIX) is 1.29 and it was updated on 2024-07-27 07:01:05.

Is Autonomix Medical, Inc. Common Stock (AMIX) overvalued or undervalued?

Currently Autonomix Medical, Inc. Common Stock (AMIX) is in undervalued.

News

From:

To:

News
Why Is Autonomix Medical (AMIX) Stock Down 17% Today? Autonomix Medical (NASDAQ: AMIX ) stock is taking a beating on Tuesday after the development stage medical device company saw its shares undergo a rally yesterday. That came as it provided updates on its pancreatic cancer pain management device. Tue, Jul. 16, 2024
Why Is Autonomix Medical (AMIX) Stock Up 120% Today? Medical device firm Autonomix Medical (NASDAQ: AMIX ) popped into traders' radar on Monday, peaking at 150% before engaging in choppy trading. An announcement of a licensing agreement with RF Innovations, a privately held medical technology specialist, catapulted sentiment. Mon, Jul. 15, 2024
Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company's ongoing human clinical trial Wed, Jul. 03, 2024
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Mon, Jun. 17, 2024
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has received Ethics Committee approval of the protocol amendment for its ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. The primary objective of the PoC human clinical trial is to successfully ablate relevant nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region. Mon, Jun. 03, 2024

Press Releases

StockPrice Release
Autonomix medical, inc. (nasdaq: amix) to participate in the virtual investor closing bell series 07/22/2024
Autonomix medical, inc. (nasdaq: amix) participates in virtual investor “what this means” segment covering technology license agreement 07/18/2024
Autonomix medical, inc. (nasdaq: amix) reviews positive results seen in pancreatic cancer pain trial in virtual investor “what this means” segment 07/03/2024
Autonomix enhances executive leadership team with appointment of proven medical technology leader, brad hauser, as president and chief executive officer 06/17/2024
Autonomix announces approval of protocol amendment by ethics committee upon completion of all lead-in patients in ongoing human clinical trial 06/03/2024
Autonomix medical, inc. reports full year 2024 financial results and provides corporate update 05/31/2024
Autonomix preclinical study successfully demonstrates that nerve ablation can slow tumor metastasis in pancreatic cancer 05/23/2024
Autonomix medical, inc. (nasdaq: amix) to participate in the virtual investor closing bell series 05/14/2024
Autonomix to present at live! with webull corporate connect: virtual biotech investment webinar 04/24/2024
Autonomix announces issuance of u.s. patent covering proprietary catheter-based technology for the treatment of cancer related pain 04/16/2024
Autonomix announces positive findings from preclinical study demonstrating potential to improve renal denervation 04/09/2024
Autonomix to participate in the virtual investor lunch break: the team behind the amix ticker 04/08/2024
Autonomix to present at the medinvest biotech & pharma investor conference 03/27/2024
Autonomix (nasdaq: amix) to present at the benzinga virtual healthcare summit 2024 03/20/2024
Autonomix appoints jennifer cook as chief business officer 03/19/2024
Autonomix completes first three patient procedures in human clinical trial targeting multi-billion-dollar pancreatic cancer market 03/14/2024
Autonomix enrolls first patients in human clinical trial targeting multi-billion-dollar pancreatic cancer market 03/06/2024
Autonomix signs key clinical agreements in preparation to begin march 2024 human clinical trial 02/29/2024
Autonomix medical, inc. (nasdaq: amix) to participate in the virtual investor lunch break: the autonomix opportunity 02/23/2024
Autonomix begins human poc clinical trial targeting multi-billion-dollar pancreatic cancer market 02/16/2024
Autonomix medical, inc. reports third quarter fy2024 financial results and reiterates upcoming key milestones 02/14/2024
Autonomix medical, inc. (nasdaq:amix) to present at integrous big hearts, big ideas virtual investor conference 02/09/2024
Autonomix medical, inc. receives ethics committee authorization for proof-of-concept human clinical study evaluating proprietary ablation technology for treatment of pancreatic cancer pain 02/06/2024
Autonomix medical, inc. (nasdaq: amix) to present at the virtual investor new to the street event 02/01/2024
Autonomix medical, inc. to ring the nasdaq stock market closing bell on thursday, february 1, 2024 01/31/2024
Autonomix medical, inc. completes $8,000,000 transaction for exclusive worldwide rights to technology for cardiology field use – over 100 patents in portfolio 01/30/2024
Autonomix medical, inc. completes transaction for exclusive worldwide rights to technology for cardiology field use 01/30/2024
Autonomix medical, inc. (nasdaq: amix) commences trading on nasdaq 01/29/2024

More Headlines

News
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system 05/31/2024
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass 05/23/2024
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series Live webcast on Thursday, May 16 th at 4:00 PM ET THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Thursday, May 16, 2024 at 4:00 PM ET. As part of the event, Lori Bisson, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook. 05/14/2024
Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Live webcast on Wednesday, May 1 st at 3:20 PM ET THE WOODLANDS, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:20 PM ET. 04/24/2024
Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain Patent portfolio with over 100 patents, issued and pending, protects technology targeting a $100 billion market opportunity 04/16/2024
Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation Preclinical study demonstrates potential of Autonomix technology to make renal denervation safer and more effective 04/09/2024
Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker Live webcast with members of the Autonomix management team, on Thursday, April 11 th at 12:00 PM ET 04/08/2024
Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference Live webcast presentation on Thursday, April 4 th at 3:55 PM ET THE WOODLANDS, TX, March 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Thursday, April 4, 2024 at 3:55 PM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. 03/27/2024
Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024 Live webcast presentation on Wednesday, March 20 th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced today that Lori Bisson, Chief Executive Officer of Autonomix will present at the Benzinga Virtual Healthcare Summit 2024 on Wednesday, March 20, 2024 at 11:50 AM ET. Benzinga's Virtual Healthcare Summit is a virtual event where the brightest minds in healthcare, influential companies, analysts, and thought leaders converge to shape the future of health. 03/20/2024
Autonomix Appoints Jennifer Cook as Chief Business Officer Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands 03/19/2024
Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer 03/14/2024
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer 03/06/2024
Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation 02/29/2024
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29 th at 12:00 PM ET 02/23/2024
Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer 02/16/2024
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer in Q1 CY2024 Cash runway to fund operations into Q1 CY2025 THE WOODLANDS, TX, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, reported financial results yesterday for the third quarter FY2024 ended December 31, 2023 and provided a corporate update. Recent Highlights Closed $11.2 million in gross proceeds from initial public offering (“IPO”) and commenced trading on NASDAQ under the ticker symbol “AMIX”; Completed $8,000,000 all stock-based transaction for exclusive worldwide rights to technology for cardiology field use; Completed preclinical safety study to support program advancement into first in human clinical study to treat pancreatic cancer pain through transvascular ablation; Completed formation of engineering development team; Received Ethics Committee authorization for proof-of-concept (“PoC”) human clinical study evaluating proprietary ablation technology for treatment of pancreatic cancer pain; and Launched corporate social media channels: X , LinkedIn , Instagram and Facebook. 02/14/2024
Autonomix Medical, Inc. (NASDAQ:AMIX) to Present at Integrous Big Hearts, Big Ideas Virtual Investor Conference Webcast presentation on Wednesday, February 14th at 10:30 AM EST THE WOODLANDS, TX / ACCESSWIRE / February 9, 2024 / Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will present at Integrous Communications' Big Hearts, Big Ideas Virtual Investor Conference on Wednesday, February 14, 2024 at 10:30 AM EST. In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. 02/09/2024
Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer 02/06/2024
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event Live moderated webcast with members of the Autonomix management team on Wednesday, February 7 th at 10:00 AM ET 02/01/2024
Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024 THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Company will ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024 to celebrate the closing of its initial public offering and listing onto Nasdaq. 01/31/2024
Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix's development and strategic opportunities THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has regained exclusive worldwide rights to its technology for cardiology field use from Impulse Medical, Inc. In December 2021, Autonomix granted Impulse Medical, Inc., a license to its technology for use in the field of cardiology. In July 2023, the Company entered into a termination agreement for the license agreement in exchange for the issuance, upon the closing of its initial public offering, of a warrant to purchase the number of shares of common stock based upon a fixed value of $8 million divided by the price per share in the offering. 01/30/2024
Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix's development and strategic opportunities THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has regained exclusive worldwide rights to its technology for cardiology field use from Impulse Medical, Inc. In December 2021, Autonomix granted Impulse Medical, Inc., a license to its technology for use in the field of cardiology. In July 2023, the Company entered into a termination agreement for the license agreement in exchange for the issuance, upon the closing of its initial public offering, of a non-cash warrant to purchase the number of shares of common stock based upon a fixed value of $8 million divided by the price per share in the offering. 01/30/2024

Unlock

AMIX Ratings Summary

AMIX Quant Ranking

What is Autonomix Medical, Inc. Common Stock's stock price?

Is Autonomix Medical, Inc. Common Stock (AMIX) overvalued or undervalued?

Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update

Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker

Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference

Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

Autonomix Appoints Jennifer Cook as Chief Business Officer

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity

Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones

Autonomix Medical, Inc. (NASDAQ:AMIX) to Present at Integrous Big Hearts, Big Ideas Virtual Investor Conference

Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event

Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024

Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio

Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt